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The antigen specificity of HCMV-specific cytotoxic T cells (CTL) was investigated in healthy adult seropositive donors by
analyzing the frequency of CTL precursors (CTLp) against six different HCMV-encoded proteins. HCMV-specific, CD8/ CTL
clones from two donors were also characterized. The precursor frequency analysis showed that a major phosphoprotein
of HCMV, pp65 (UL83), was the immunodominant CTL target antigen in healthy seropositive adults. The frequency of CTLp
specific for different HCMV proteins ranged from 1/12,000 for pp65 to 1/100,000 for gB (UL55), gH (UL75), pp50 (UL44),
and pp28 (UL98). Characterization of the HCMV-specific CTL clones from two donors revealed that the majority of clones
lysed targets expressing pp65 and that none of the clones recognized other HCMV proteins. q 1996 Academic Press, Inc.
Human cytomegalovirus (HCMV) is an important cause the requirement for endogenous viral replication and
of morbidity and mortality in immunodeficient individuals gene expression (14). Subsequent investigations, includ-
such as allograft recipients and patients with AIDS ing a recent study using cyanogen bromide (CNBr)-di-
(1–4). HCMV is also the most frequent cause of congeni- gested peptides, revealed that the major structural pro-
tal infection and a leading cause of sensorineural hear- tein, phosphoprotein 65 (pp65), is an important target
ing loss and brain disease in children (5, 6). The impor- antigen of the HCMV-specific CTL response (15–17).
tance of cell-mediated immune responses, especially the However, each of these studies was limited by the use
activity of CD8/, class I MHC-restricted, HCMV-specific of only one or two viral antigens. To further investigate
cytotoxic T cells (CTL), has been documented by studies the antigen specificity of CTL following natural infection
in the murine CMV (MCMV) model as well as in human with HCMV, we examined virus-specific CTL precursor
transplant recipients. In the murine model, adoptive (CTLp) frequency in seropositive adult volunteers using
transfer of virus-specific T cells in immunosuppressed vaccinia recombinant viruses expressing HCMV struc-
mice can prevent or resolve interstitial pneumonitis and tural proteins gB (UL55), gH (UL75), pp65 (UL83), pp150
reverse hematopoietic dysfunction (7). The recovery from (UL32), and pp28 (UL98), and the nonstructural protein,
invasive HCMV infection in human bone marrow and pp50 (UL44). HCMV-specific CD8/ CTL clones were
renal transplant recipients has been correlated with the generated from two donors and their antigen specificity
presence of HCMV-specific CTL activity (8, 9). Further- was characterized.
more, adoptive transfer of autologous virus-specific Study subjects included 11 HCMV-seropositive adult
CD8/ CTL clones led to the reconstitution of HCMV- healthy volunteers. Autologous fibroblast cell cultures
specific CTL activity and protection from invasive HCMV and EBV-transformed lymphoblastoid cell lines (LCL)
disease in bone marrow allograft recipients (10, 11). were established from each of the participants using
The antigen specificity of HCMV-specific, CD8/ CTL standard methods (14). HCMV, AD169 strain, was propa-
has been incompletely defined. A study of two HCMV- gated and virus stocks were prepared as described pre-
seropositive individuals demonstrated CTL recognition viously (14, 18). The vaccinia recombinant virus encoding
of the major immediate early protein (pp72) and envelope the full-length sequence of HCMV AD169 gB and gH
glycoprotein gB, but the majority of HCMV-specific CTL has been previously described (19, 20). The recombinant
recognized other undefined viral antigens (12, 13). Riddell vaccinia viruses expressing pp65, pp150, and pp28 were
et al. showed that the dominant CTL response was di- all constructed in a fashion similar to that described as
rected against structural HCMV proteins that are pro- above. Open reading frames encoding the respective
cessed and presented by HCMV-infected cells without genes were obtained from genomic clones provided by
Drs. Michael Mach and Bodo Plachter (University of Er-
langen, Germany). The recombinant vaccinia virus ex-1 To whom correspondence and reprint requests should be ad-
dressed. Fax: (205) 975-6549. E-mail: pedp052@uabdpo.dpo.uab.edu. pressing pp50 (UL44) was constructed from a PCR-de-
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FIG. 1. Limiting dilution analysis of HCMV-specific CTL in four HCMV-seropositive donors. The individual wells were assayed against autologous
fibroblasts infected with AD169, or vaccinia recombinant viruses encoding pp65, pp150, gB, gH, pp28, and pp50. No significant lysis of mock-
infected or wild-type vaccinia virus-infected targets was observed. There no lysis of MHC-mismatched targets (data not shown). The precursor
frequency of HCMV-specific CTL ranged between 1/7500 (donor PW) and 1/19,000 (donor DA). The CTL against pp65 were present at a frequency
range between 1/12,000 and 1/28,000. The frequency of pp150-specific CTL ranged between 1/46,000 and 1/86,000. The frequency of CTL recognizing
targets expressing gB, gH, pp28, and pp50 was 1/100,000.
rived UL44 clone amplified from strain AD169 DNA. The determined by a standard 4-hr chromium release assay
and the percentage specific lysis was calculated (14).recombinant viruses were monitored for expression of
the specific HCMV gene product by both immunofluores- Mock-infected, wild-type vaccinia virus-infected and
MHC-mismatched targets were used as controls. Thecence and immunoblotting using previously described
monoclonal antibodies (19–21). expression of CD3, CD4, and CD8 was determined with
flow cytometry (data not shown).Limiting dilution cultures to estimate the CTLp fre-
quency recognizing HCMV were performed as described HCMV-specific CTL were present at a frequency range
between 1/7500 (donor PW) and 1/19,000 (donor DA).previously (12, 22). The 11- to 14-day cultures were di-
vided equally and HCMV-specific, HLA-restricted CTL ac- The recognition of HCMV gene products including gB
(UL55), gH (UL75), pp65 (UL83), pp150 (UL32), pp28tivity was determined against autologous and HLA-mis-
matched fibroblasts infected with AD169 or various vac- (UL98), and pp50 (UL44) by HCMV-specific CTL was ex-
amined. The CTLp frequency in four seropositive donorscinia recombinants expressing individual HCMV gene
products. The data were analyzed as described pre- is shown in Fig. 1. The frequency of HCMV-specific CTL
that recognized the envelope glycoproteins gB and gHviously and standard limiting dilution plots were obtained
(12, 22). The frequency of HCMV-specific CTLp was esti- was beyond the limits of the assay with frequencies
greater than 1/100,000. In contrast, HCMV pp65-specificmated as the input cell number that resulted in 37% nega-
tive cultures against a specific target. Significant 51Cr CTL were present at a frequency of 1/12,000 to 1/28,000
in the study subjects. The frequency pp150-specific CTLrelease in each well was determined if the counts were
3 SD above the lysis observed in the ‘‘feeder cell only’’ ranged between 1/46,000 and 1/86,000. Similar to the
frequency of gB- and gH-specific CTL, pp28- and pp50-control wells. CD8/ HCMV-specific CTL clones were
generated from 14-day CTL cultures using previously de- specific CTL activity was not detected within the limits
of the assay. There was no specific lysis of MHC-mis-scribed methods (14). The specificity of CTL clones was
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TABLE 1
Cytolytic Activity of Class I MHC Restricted CD8/ CTL Clones from the Donor WB
% Specific lysis
CTL clone Mock AD169 Vac Vav/gB Vac/gH Vac/65 Vac/150 Vac/28 Vac/50
1A3 7 34* 10 12 9 29* 12 16 10
2A4 9 38* 12 14 11 34* 15 17 15
2A8 6 43* 13 16 14 32* 10 15 19
3A6 10 36* 15 17 10 19 11 14 18
1B4 7 28* 9 11 12 13 12 9 11
1B9 6 36* 13 15 11 16 15 12 15
3B9 8 29* 11 16 13 27* 8 11 13
2D3 9 34* 9 14 14 16 9 13 12
3D6 11 32* 14 12 10 31* 15 15 16
2E4 7 29* 12 9 15 39* 11 16 12
3E8 12 46* 15 13 12 35* 14 18 14
* Significant specific lysis.
matched fibroblasts infected with vaccinia recombinant graft donors, CTL response to HCMV was shown to be
restricted to a small number of epitopes derived fromviruses.
HCMV-specific CTL clones were examined for the cy- virion structural proteins (14). Furthermore, an investiga-
tion of bone marrow transplant recipients suggested thattolytic activity against autologous targets infected with
the panel of recombinant vaccinia viruses. HCMV-spe- a single structural phosphoprotein, pp65, was likely an
immunodominant CTL target antigen (15, 16). However,cific CTL clones were generated from two seropositive
donors (PW and WB) and were shown to be CD8/ by the large number of open reading frames encoded by
HCMV (200) raised the possibility that additional viralflow cytometry (data not shown). As can be seen in Table
1, 7/12 (59%) HCMV-specific CTL clones derived from proteins could serve as dominant targets of virus-specific
CTL. We examined this possibility by studying the CTLthe donor WB also recognized autologous targets in-
fected with vac/pp65. There was no lysis of targets ex- responses against multiple HCMV proteins in healthy
HCMV-seropositive individuals. The results of the precur-pressing other HCMV gene products. Similarly, 5/8 (67%)
clones generated from donor PW recognized target cells sor frequency analysis have shown that pp65 was a dom-
inant CTL antigen in healthy HCMV-seropositive individu-infected with vac/pp65 (data not shown). All the clones
from both donors exhibited CTL activity against autolo- als. We could also demonstrate consistent CTL re-
sponses in almost half the study subjects against pp150gous target cells infected with AD169. In contrast, none
of the clones recognized target cells expressing gB, gH, (data not shown). However, the frequency of CTL precur-
sors against this antigen was considerably lower thanpp150, pp28, or pp50. No specific lysis of mock-infected,
wild-type vaccinia-infected autologous fibroblasts or the pp65-specific CTL. Furthermore, none of the CTL
clones that were examined exhibited cytolytic activityMHC-mismatched targets expressing various HCMV
gene products was observed. against target cells expressing pp150.
The results of the characterization of antiviral CD8/Although the importance of CD8/ CTL responses in
controlling herpesvirus infections is well accepted, only CTL clones from two of the study individuals revealed
that a majority of the clones also recognized and lysedrecently has the contribution of CTL responses against
individual viral proteins to the outcome of infection been target cells infected with vaccinia virus recombinant en-
coding pp65. Given the polymorphism of HLA pheno-addressed. The specificity of CTL responses following
herpesvirus infection in small animals has been shown to types in humans, one would anticipate that the antigen
specificity of CTL response would be more diverse thanbe directed against a limited number of peptide epitopes
derived from a relatively few immunodominant viral pro- that observed in this study. As there is considerable poly-
morphism of the class I MHC haplotypes in an outbredteins (23, 24). Studies in BALB/c mice identified the prod-
uct of the major immediate early gene (MIE-1) as the population, it seemed likely that different HCMV antigens
could act as immunodominant CTL targets depending onimmunodominant CTL target antigen and immunization
with a vaccinia recombinant expressing the MIE-1 pro- the MHC haplotype of a given individual. Furthermore,
even a single cycle of in vitro stimulation with antigen(s)tein, pp89, provided protection from lethal MCMV chal-
lenge (25, 26). Similar results have been reported in could bias selection of CTL clones for that antigen(s) and
thus lead to an artifactual representation of clonotypes.guinea pigs immunized with a single gene product of
varicella-zoster virus (27). In studies of bone marrow allo- However, we have utilized virus-infected autologous fi-
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